within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BB09_Gliclazide;
model Gliclazide 
   extends Pharmacolibrary.Drugs.ATC.A.A10BB09;

  annotation(Documentation(
    info ="<html><body><p>Gliclazide is a second-generation sulfonylurea antidiabetic drug that stimulates insulin secretion from pancreatic beta cells. It is used orally for the management of type 2 diabetes mellitus and is approved for use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single oral 80 mg dose.</p><h4>References</h4><ol><li><p>Shaik, M, et al., &amp; Kilari, EK (2018). Population pharmacokinetics of gliclazide in normal and diabetic rabbits. <i>Biopharmaceutics &amp; drug disposition</i> 39(5) 265–274. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2132&quot;>10.1002/bdd.2132</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29679474/&quot;>https://pubmed.ncbi.nlm.nih.gov/29679474</a></p></li><li><p>Al-Omary, FAM (2017). Gliclazide. <i>Profiles of drug substances, excipients, and related methodology</i> 42 125–192. DOI:<a href=&quot;https://doi.org/10.1016/bs.podrm.2017.02.003&quot;>10.1016/bs.podrm.2017.02.003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28431776/&quot;>https://pubmed.ncbi.nlm.nih.gov/28431776</a></p></li><li><p>Sampathi, S, et al., &amp; Dyawanapelly, S (2022). Pharmacokinetics and Anti-Diabetic Studies of Gliclazide Nanosuspension. <i>Pharmaceutics</i> 14(9) –. DOI:<a href=&quot;https://doi.org/10.3390/pharmaceutics14091947&quot;>10.3390/pharmaceutics14091947</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36145695/&quot;>https://pubmed.ncbi.nlm.nih.gov/36145695</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Gliclazide;
